293 completed, 76 unknown, 58 recruiting, 25 terminated. 115 Phase 3, 106 Phase 4, 57 Phase 2, 51 Phase 1, 38 Not applicable.
Follow Rivaroxaban: new trials by email Literature Review of Rivaroxaban trials Research Report on Rivaroxaban
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study to Observe the Pattern of Use and Safety of Rivaroxaban in Children Under 2 Years Old With Venous Thromboembolism (VTE) Rivaroxaban (Xarelto, BAY59-7939), Standard of care (SOC) - Venous Thromboembolism, Children Under 2 Years | Not yet recruiting | Bayer | 850 | 2027-09-01 | 2026-10-02 | |
| Anti-inflammatory and Anti-thrombotic Therapy With colcHicine and Low Dose Rivaroxaban for Major Adverse Cardiovascular Events Reduction in Ischemic Stroke Rivaroxaban 2.5 Mg Oral Tablet, Colchicine 0.5 MG, Placebo Rivaroxaban - Ischemic Stroke | Phase 4 | Not yet recruiting | Brazilian Clinical Research Institute | 4500 | 2027-01-01 | 2026-10-30 |
| To Evaluate The Efficacy And Safety Of Rivaroxaban In Combination With Aspirin Compared With Aspirin Monotherapy In Patients With Stable Coronary Artery Disease (CAD) and High Ischemic Risk rivaroxaban plus aspirin, Aspirin 75 mg daily - Stable Coronary Artery Disease (CAD), Myocardial Infarction | Not applicable | Not yet recruiting | Republican Specialized Scientific and Practical Medical Center of Cardiology | 200 | 2026-11-05 | 2026-11-10 |
| Combination Antithrombotic Treatment for Prevention of Recurrent Ischemic Stroke in IntraCranial Atherosclerotic diseaSe (CATIS- ICAS) Rivaroxaban, ASA - Ischemic Stroke, Intracranial Atherosclerosis | Phase 3 | Not yet recruiting | Population Health Research Institute | 1172 | 2026-09-30 | 2026-09-01 |
| Comparison of DOACs and LMWH for Thromboprophylaxis After Total Knee Arthroplasty Apixaban, Rivaroxaban, Enoxaparin (LMWH) - Total Knee Arthroplasty, Venous Thromboembolism | Not applicable | Recruiting | Military Hospital of Tunis | 138 | 2026-09-15 | 2026-10-16 |
| Study on Anti-Thrombotic Regimens for Secondary Prevention in Ischemic Stroke Patients With Possible Benefit From Anticoagulation Therapy Rivaroxaban, or Edoxaban , or Apixaban , or Dabigatran, Aspirin - Stroke, Acute Ischemic Stroke | Phase 3 | Not yet recruiting | Second Affiliated Hospital, Zhejiang University, School of Medicine | 680 | 2026-08-15 | 2026-08-05 |
| Reducing Adverse Vascular Outcomes With Factor XI Inhibition in Adult Participants With Peripheral Artery Disease REGN7508, REGN9933, Placebo - Peripheral Artery Disease (PAD) | Phase 3 | Recruiting | Regeneron Pharmaceuticals | 7050 | 2026-07-10 | 2026-11-05 |
| STRATEGY-PE: Real-World Treatment Strategies for Intermediate-High Risk Pulmonary Embolism Anticoagulants, Thrombolytic Agents, Mechanical Thrombectomy Devices - Pulmonary Embolism, Venous Thromboembolism | Not yet recruiting | Nanjing First Hospital, Nanjing Medical University | 1300 | 2026-06-01 | 2026-05-22 | |
| Comparing the Safety and Efficacy of Apixaban and Rivaroxaban Apixaban, Rivaroxaban - Atrial Fibrillation | Phase 4 | Recruiting | VA Office of Research and Development | 10000 | 2026-06-01 | 2026-09-23 |
| Comparison of Aspirin Alone Versus Low-Dose Rivaroxaban Plus Aspirin in Chronic Limb-Threatening Ischemia Aspirin tablet, Low-Dose Rivaroxaban Plus Aspirin, - Limb Ischemia | Early Phase 1 | Recruiting | King Edward Medical University | 78 | 2026-06-01 | 2026-09-22 |
| Direct Oral Novel Anticoagulants for Patients With High-risk Gastroesophageal Variceal Bleeding and Portal Vein Thrombosis Rivaroxaban - Portal Vein Thrombosis, Anticoagulant Therapy | Not applicable | Not yet recruiting | Shanghai Zhongshan Hospital | 175 | 2026-06-01 | 2026-05-22 |
| Multicenter Trial of Antithrombotic Strategies in Acute Coronary Syndrome With Coronary Artery Ectasia Aspirin 100 mg, Clopidogrel 75 mg, Rivaroxaban 15 mg - Coronary Artery Ectasia, Acute Coronary Syndromes (ACS) | Phase 4 | Recruiting | Instituto Nacional de Cardiologia Ignacio Chavez | 326 | 2026-02-11 | 2026-04-09 |
| A Study to Investigate Andexanet Dosing and the Interaction Between Andexanet and Subsequent Enoxaparin in Healthy Participants Andexanet alfa, Rivaroxaban, Apixaban - Healthy Participants | Phase 1 | Completed | AstraZeneca | 191 | 2026-01-19 | 2026-07-09 |
| Dabigatran vs. Oral Anti-Xa Inhibitors in S. Aureus Bacteremia Dabigatran, Apixaban, edoxaban - Staphylococcus Aureus Endocarditis, Staphylococcus Aureus Septicemia | Phase 4 | Recruiting | McGill University Health Centre/Research Institute of the McGill University Health Centre | 300 | 2026-01-15 | 2026-09-24 |
| A Real World Evidence Retrospective Data Collection Study of Edoxaban and Rivaroxaban Edoxaban, Rivaroxaban - Atrial Fibrillation, Renal Dysfunction | Completed | Daiichi Sankyo | 8265 | 2025-12-25 | 2026-10-15 | |
| Hip Fracture Surgery Arterial and Venous Thrombotic Events Prevention rivaroxaban and ASA, Low-molecular weight heparin, Fondaparinux - Hip Fracture Surgery, Cardiovascular Prevention | Phase 3 | Not yet recruiting | McMaster University | 100 | 2025-12-01 | 2025-11-14 |
| Rivaroxaban vs Enoxaparin After Cesarean Section: Laboratory Thromboprophylaxis Outcomes Rivaroxaban, Enoxaparin 40 mg - Postpartum Period, Cesarean Section Surgery | Not applicable | Recruiting | Wolfson Medical Center | 62 | 2025-12-01 | 2026-09-15 |
| Comparative Efficacy of Rivaroxaban and Enoxaparin in Post-Laparotomy DVT Prevention rivaroxaban (10mg), Enoxaparin 40 mg SC - Deep Venous Thromboses, Laparotomy Patients | Phase 4 | Recruiting | Mayo Hospital Lahore | 212 | 2025-10-10 | 2025-11-21 |
| Post-Operative Biomarker-Guided Precision Medicine For Cardiovascular Risk Reduction Rivaroxaban, Atorvastatin - Myocardial Injury After Noncardiac Surgery | Early Phase 1 | Recruiting | NYU Langone Health | 50 | 2025-10-07 | 2026-04-06 |
| Rivaroxaban for Slow Coronary Flow After PCI in STEMI Dual Antiplatelet (DAPT) Therapy, Rivaroxaban - ST Elevation Myocardial Infarction, No-Reflow Phenomenon | Phase 4 | Not yet recruiting | Second Affiliated Hospital, Zhejiang University, School of Medicine | 60 | 2025-10-01 | 2025-09-29 |
Showing 20 of 486. Sign in to see all of them.
Atrial Fibrillation (114) · Venous Thromboembolism (89) · Stroke (59) · Venous Thrombosis (54) · Thrombosis (45) · Pulmonary Embolism (36) · Hemorrhage (26) · Thromboembolism (22) · Ischemic Stroke (21) · Coronary Artery Disease (20) · Acute Coronary Syndrome (18) · Neoplasms (18) · Peripheral Arterial Disease (17) · Cardiovascular Diseases (15) · Embolism (15)
Bayer (113) · Janssen Research & Development, LLC (10) · Assistance Publique - Hôpitaux de Paris (8) · Brigham and Women's Hospital (8) · Ottawa Hospital Research Institute (8) · Population Health Research Institute (8) · Insel Gruppe AG, University Hospital Bern (7) · Pfizer (7) · Second Affiliated Hospital, Zhejiang University, School of Medicine (7) · Bristol-Myers Squibb (5) · Janssen Scientific Affairs, LLC (5) · Centre Hospitalier Universitaire de Saint Etienne (4) · Ottawa Heart Institute Research Corporation (4) · Asan Medical Center (3) · Assiut University (3)
United States (99) · Canada (82) · Germany (71) · France (67) · China (64) · United Kingdom (58) · Italy (47) · Netherlands (47) · Spain (46) · Belgium (43) · South Korea (43) · Brazil (40) · Sweden (39) · Denmark (37) · Austria (33)
Shirley Wang, PhD, ScM (7) · Jun-Wen Wang, MD (3) · Lana Castellucci, MD, FRCPC (3) · Chao Gao, M.D., Ph.D. (2) · Fang Liu, MD (2) · Gunnar H Gislason, MD, PhD (2) · Ling Tao, M.D., Ph.D. (2) · Madeleine Durand, MD, MSc, FRCPC (2)
PMID 37591523, PMID 40163217, PMID 31535314, PMID 34172290, PMID 22371186, PMID 25698905, PMID 29132879, PMID 29132880, PMID 29976287, PMID 31420317, PMID 35244208, PMID 38941511, PMID 21128814, PMID 21570509, PMID 21830957, PMID 22077192, PMID 22664783, PMID 23013426, PMID 23829521, PMID 24053656, PMID 24341332, PMID 24432872, PMID 25717286, PMID 25750589, PMID 25851062, PMID 27030066, PMID 27535349, PMID 28844192, PMID 30121419, PMID 31699660, PMID 31975354, PMID 32657973, PMID 33766266, PMID 34022170, PMID 34755519, PMID 35389229, PMID 36700520, PMID 38189593, PMID 38844941, PMID 40875095, PMID 42389777, PMID 10591382, PMID 1100130, PMID 11546885, PMID 12917889, PMID 15189396, PMID 15234649, PMID 15811953, PMID 15842354, PMID 18094721
2014 (8), 2015 (7), 2016 (4), 2019 (4), 2023 (4), 2017 (3), 2025 (3), 2008 (2), 2009 (2), 2004 (1), 2005 (1), 2018 (1), K23HL151871 (1), R34HL113404 (1), R34HL173301 (1)